

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Issuer


**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

September 25, 2002

Oncolytics Biotech Inc.

Commission File No. 000-31062
(Translation of registrant's name into English)

Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada, T2N 1X7
(Address of principal executive office)



Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.

Form 20-F _____ Form 40-F x

Indicate by check mark whether the registrant by furnishing the information contained in this
Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Act of 1934.

Yes _____ No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection
with Rule 12g3-2(b): 82- N/A

A handwritten signature or scribble in the bottom right corner of the page.

Exhibit Number

1.

Exhibit

News Release Dated September 25, 2002

Page 1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Oncolytics Biotech Inc.

Dated September 25, 2002

By:

A handwritten signature in black ink, appearing to be 'BT' or 'Brad Thompson', written over a horizontal line.

Brad Thompson, Ph.D.
President & CEO

Exhibit Index

Exhibit Number	Exhibit	Page
1.	News Release Dated September 25, 2002	1



210, 1167 Kensington Cr. N.W.
Calgary, Alberta
Canada T2N 1X7

For Immediate Release

Oncolytics Biotech Inc. Announces Issuance of Fifth U.S. Patent Covering REOLYSIN® Technology

CALGARY, Alberta, September 25, 2002 -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") has been granted U.S. Patent 6,455,038 entitled "Reovirus for the treatment of cellular proliferative disorders." This patent covers the use of various strains and combinations of reoviruses, wherein one or more of the reoviruses may be immunoprotected, as a treatment for Ras-mediated proliferative disorders, such as neurofibromatosis and cancer in an immunocompetent mammal.

"We are pleased with the patent protection Oncolytics is securing," said Dr. Matt Coffey, Vice President of Product Development. "With the issuance of our fifth U.S. patent covering REOLYSIN® technology, the Company is becoming well-positioned in this novel therapeutic area. We have over 100 additional patent applications pending worldwide and we expect to continue to expand our patent portfolio for REOLYSIN®."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of the human reovirus (REOLYSIN®) as a potential cancer therapeutic. Oncolytics' researchers have demonstrated that the reovirus is able to selectively kill cancer cells and, *in vitro*, kill human cancer cells derived from many types of cancer including breast, prostate, pancreatic and brain tumours. Research has also yielded successful cancer treatment results in a number of animal models. Phase I clinical trial results have indicated that there were no toxicology-related issues with the administration of the reovirus, and that the reovirus demonstrated activity in injected tumours. Oncolytics is currently conducting a T2 prostate cancer trial, and a Phase I/II recurrent malignant glioma (brain cancer) trial.

This press release contains forward looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward looking statements, including the Company's belief as to the potential of REOLYSIN® as a cancer therapeutic, the Company's expectations regarding the issuance of additional patents and the benefits provided by current and prospective patents, and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN® as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN®, the development of alternative products or treatments by the Company's competitors, the inability of the Company to defend its patents from infringement by third parties, the risk that the Company's patents may be subsequently shown to be invalid, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward looking statements. The Company does not undertake to update these forward looking statements.

FOR FURTHER INFORMATION PLEASE CONTACT:

For Canada:
Oncolytics Biotech Inc.
Dr. Matt Coffey
210, 1167 Kensington Cr NW
Calgary, Alberta T2N 1X7
Tel: 403.670.7377
Fax: 403.283.0858
www.oncolyticsbiotech.com

For Canada:
The Equicom Group Inc.
Jason Hogan
20 Toronto Street
Toronto, Ontario M5C 2B8
Tel: 416.815.0700 ext. 222
Fax: 416.815.0080
jhogan@equicomgroup.com

For United States:
The Investor Relations Group
Gino De Jesus or Dian Griesel, Ph.D.
50 Pine Street, 6th Floor
New York, NY 10005
Tel: 212.825.3210
Fax: 212.825.3229
theproteam@aol.com